VRCA vs NVCR vs NKTR vs DERM

For growth investors, Verrica Pharmaceuticals Inc.

(VRCA) is the stronger pick with 370. 2% revenue growth year-over-year, versus -43. 9% for Nektar Therapeutics (NKTR). Analysts rate Verrica Pharmaceuticals Inc. (VRCA) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Journey Medical Corporation (DERM) delivered a total return of -47.

4%, compared to -92. 8% for Verrica Pharmaceuticals Inc. (VRCA). Over 10 years, the gap is even starker: NVCR returned +30. 3% versus VRCA's -95. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Journey Medical Corporation (DERM) is the lower-risk stock at 1.

82β versus NovoCure Limited's 2. 20β — meaning NVCR is approximately 21% more volatile than DERM relative to the S&P 500. On balance sheet safety, Verrica Pharmaceuticals Inc. (VRCA) carries a lower debt/equity ratio of 7% versus 166% for Nektar Therapeutics — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Verrica Pharmaceuticals Inc.

(VRCA) is pulling ahead at 370. 2% versus -43. 9% for Nektar Therapeutics (NKTR). On earnings-per-share growth, the picture is similar: Verrica Pharmaceuticals Inc. grew EPS 88. 6% year-over-year, compared to -242. 9% for Journey Medical Corporation. Over a 3-year CAGR, VRCA leads at 57. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

NovoCure Limited (NVCR) is the more profitable company, earning -20.

8% net margin versus -297. 1% for Nektar Therapeutics — meaning it keeps -20. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NVCR leads at -23. 5% versus -236. 8% for NKTR. At the gross margin level — before operating expenses — NKTR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for DERM: 135.

0% to $11. 75.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Journey Medical Corporation (DERM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding.

Verrica Pharmaceuticals Inc. (VRCA) carries a higher beta of 2. 19 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (DERM: -47. 4%, VRCA: -95. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: VRCA is a small-cap high-growth stock; NVCR is a small-cap quality compounder stock; NKTR is a small-cap quality compounder stock; DERM is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.